OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1 The majority of chronic phase-chronic myeloid leukaemia (CP-CML) patients respond well to the first generation tyrosine kinase inhibitor, imatinib. However, 25-30% of patients fare less well, exhibiting suboptimal response or treatment failure. We have demonstrated that the functional activity of the OCT-1 protein (termed OCT-1 activity) assayed in patient mononuclear cells before the start of imatinib therapy is a key determinant of both short-and long-term response to imatinib in previously untreated CP-CML.
1,2 A greater proportion of patients with high OCT-1 activity (4 median value defined in the Tidel study of 7.2 ng per 200 000 cells) 1 achieve major molecular response (MMR) when compared with patients with low OCT-1 activity (89 vs 55%; P ¼ 0.007). Furthermore, a low OCT-1 activity is significantly associated with lower overall survival to 5 years (87 vs 96%; P ¼ 0.028) and event-free survival (48 vs 74%; P ¼ 0.03), as well as a higher Abl kinase domain mutation rate (21 vs 4%; P ¼ 0.047). The interpatient variability observed in OCT-1 activity remains unexplained. It has been suggested that the level of OCT-1 mRNA is predictive of response to imatinib, 3 however this has yet to be demonstrated in a large cohort of previously untreated patients. It is possible that non-synonymous, single-nucleotide polymorphisms (SNPs) that result in an altered OCT-1 protein may well impact on the functional activity of this protein and, therefore, on response to therapy.
In a recent publication Bazeos et al. 4 explored SNPs as possible predictive factors for imatinib response. In this study they investigated the frequency of seven previously reported SNPs in a cohort of 132 CML patients treated with imatinib in chronic phase. They also explored, the impact of four of these SNP's (R61C, P341L, G401S and rs6222342) on the achievement of MMR, and found that the G401S (rs34130495) SNP was significantly associated with a higher rate of MMR (P ¼ 0.0155).
It is interesting that this polymorphism has been previously described by Shu and Kerb 5, 6 and has been demonstrated to result in a reduced function protein with respect to transport of the model OCT-1 substrates MPP and tetraethylammonium (TEA). Thus, its association with an increased rate of MMR is surprising. It is also evident that the frequency of this SNP is low (frequency in the tested population 0.045, frequency in European Americans Shu 0.011), 5 thus its presence would not account for many cases of MMR observed in CP-CML patients treated with imatinib.
We have screened 136 newly diagnosed CP-CML patients presenting to our Centre for the presence of the commonly reported non-synonymous SNPs of OCT-1; 5 Reduced-function SNPs(R61C, G401S, C88R and P341L), loss of function SNPs (G220V and G465R) and the SNPs reported not to alter function (M408V and M420del) using direct sequencing. As demonstrated in Table 1 the most common SNP's in our patient cohort were the M408V and the M420del with observed frequencies of 0.38 and 0.29, respectively. The G220V SNP was not detectable in any patient tested and the C88R, P341L and G465R were each only detectable in one patient. These frequencies are in keeping with previous reports in European/American populations. 5 The M408V and the M420del SNPs are thought to be associated with normal transport of the model substrates TEA and MPP. 5 However, the M420del has more recently been associated with decreased transport of the diabetes drug metformin. 7 This exemplifies the considerable substrate variability in the impact of SNPs, and validates screening SNPs, with a frequency 40.10 for possible therapeutic effect.
Where SNPs were detected at sufficient frequency (n ¼ 4) we then assessed the achievement of MMR by 24 months in patients with and without SNPs. Log rank and w 2 analysis revealed that, in this cohort of patients, the presence of either R61C, G401S or M408V (homozygous or heterozygous) and M420del (homozygous or heterozygous) had no significant effect on the achievement of MMR by 24 months (P ¼ 0.949, 0.411, 0.112, 0.580, 0.442 and 0.189, respectively) Table 1. These data suggest that the presence of these SNPs is insufficient to explain the changes we observe in OCT-1 activity between patients.
As we have previously demonstrated that the functional activity of the OCT-1 protein is associated with the achievement of MMR in imatinib-treated CP-CML patients, 1,2 we then assessed whether a low OCT-1 activity was associated with the presence of a SNP in the 91/132 patients in whom both OCT-1 Activity and SNP data were available. In this cohort of 91 patients the rate of MMR was 55% in patients with low OCT-1 activity (n ¼ 48: median time to achieve MMR 24 months) and 83% in high OCT-1 activity patients (n ¼ 43: median time to achieve MMR 17 mo) (p-0.027). As demonstrated in Figures 1a-c there was no significant difference in OCT-1 activity among patients with or without the more common SNPs R61C, M408V or M420del (P ¼ 0.283, 0.126 and 0.834, respectively). Furthermore, there was no obvious difference between the percentage of patients with SNPs and low or high OCT-1 activity (Figure 1d ).
Dividing OCT-1 activity into quartiles, where quartile 1(Q1) is the lowest and Q4 the highest, we have previously demonstrated that patients with the lowest OCT-1 activity (that is, those in Q1 o4 ng per 200 000 cells) have the poorest response to imatinib and highest rate of transformation to accelerated phase or blast crisis.
2 Investigation of the percentage of patients in each quartile with one or more SNPs failed to demonstrate a difference between the quartiles (Q1, 85% of patients; Q2, 78%; Q3, 74% and Q4, 83%). Investigation of events (as defined for The International Randomised Study of Interferon versus STI571 (IRIS) trial, with the addition of loss of complete cytogenetic response) in those patients with 5-year molecular follow up (n ¼ 56), revealed no difference in the presence of SNPs between those patients with (n ¼ 20) events or those without (n ¼ 36) (data not shown).
Similarly the presence of kinase domain mutations (n ¼ 7) were associated with low OCT-1 activity (n ¼ 6/7), but were not associated with the presence of SNPs.
Because the effect of a heterozygous SNP affecting function may be more evident in the setting of low-dose exposure, and as the effect of a low OCT-1 activity can be partially overcome with dose increase, the effect of dose on MMR, in the setting of SNPs was assessed. As patients were treated on various trials encompassing varying treatment regimens ranging from 400 QD to 400 BID dosage was grouped into two cohorts, one o600 mg per day average daily dose and the other X600 mg average daily dose. As demonstrated in Table 2 , there was no significant difference in outcome on the basis of dose for the SNPs tested.
In summary, we have observed SNPs in OCT-1 for the Australian population at a similar frequency to that observed previously European/American. 5 We were unable to demonstrate any statistically significant affect of the presence of a SNP on the achievement of MMR by 24 months. Furthermore we could not show a link between SNPs and progression to accelerated phase or blast crisis, or the development of Abl kinase domain mutants. Significantly, we were also unable to demonstrate a link between SNPs and OCT-1 activity, a strong predictor of both short-and long-term response in imatinib treated CP-CML patients. Previous studies have linked the F160L SNP and disease stage (accelerated phase and blast crisis), but not the SNP alone, to loss of response or treatment failure in imatinib-treated patients; however, we did not examine this SNP in our screen of chronic phase patients. 8 In conclusion we were unable to substantiate the findings of Bazeos et al.
4 in our patient cohort. As many of these SNPs occur at very low frequency, and are mostly only found as heterozygote, screening of very large patient cohorts would be necessary to conclusively associate response with SNPs. Furthermore, because of this observed low frequency, it is likely that, although these SNPs may be of particular relevance in some patients, this association is difficult to substantiate and other factors, such as post-transcriptional events, may significantly impact the function of the OCT-1 protein, and may be of greater clinical relevance. In addition, there is significant variation in SNP frequency between races. 5 Any SNP, posttranscriptional event or race-related variation will be reflected in a functional assay of OCT-1, such as the assay we have previously described 1 . Thus, screening patients at diagnosis, before the initiation of imatinib therapy, for OCT-1 activity, provides a robust assay of the function of OCT-1 with respect to imatinib transport that has demonstrated excellent prognostic capabilities. Table 1 The observed frequency and effect on the achievement of MMR by 24 months of various non-synonymous SNPs Letters to the Editor
